New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
10:25 EDTCPIX, PRGOCumberland enters settlement with Paddock, Perrigo for Acetadote patent
Cumberland (CPIX) disclosed this morning that it entered into a settlement agreement with Paddock and Perrigo to resolve the challenges and the pending litigation between the company and each of Paddock and Perrigo (PRGO) involving its Acetadote patent. Under the agreement, Paddock and Perrigo admit that the Acetadote patent is valid and enforceable and that any Paddock or Perrigo generic Acetadote would infringe upon the Acetadote patent. In addition Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the Acetadote patent through its expiration currently scheduled for May 2026. The agreement provides, among other things, that within three days of execution, the parties will file with the respective Illinois and Delaware courts all necessary papers required to dismiss without prejudice all claims and counterclaims, motions and petitions asserted in the above referenced lawsuits In connection with the execution of the settlement agreement, Cumberland entered into a License and Supply Agreement with Paddock and Perrigo. Under the terms, if a third party receives final approval from the FDA to sell a generic Acetadote product, Cumberland will supply Perrigo with an authorized generic version of the Acetadote product. Perrigo agrees to sell the authorized generic and that it would share with Cumberland the net sales revenues.
News For CPIX;PRGO From The Last 14 Days
Check below for free stories on CPIX;PRGO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
10:01 EDTPRGOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:22 EDTPRGOPerrigo upgraded at B. Riley
As previously reported, B. Riley upgraded Perrigo to Buy from Neutral. The firm upgraded shares following the better than expected Q4 report and guidance and said it expects a return to consistent financial performance.
06:04 EDTPRGOPerrigo upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
August 14, 2014
10:06 EDTPRGOPerrigo sees FY15 revenue growth 7%-11%
Perrigo in earnings call presentation slides guided its FY15 revenue growth to 7%-11% above FY14. The company sees adjusted operating margin around 29% with an effective tax rate around 16%. Perrigo expects operating cash flow greater than $1B.
09:11 EDTPRGOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
07:55 EDTPRGOPerrigo reports Q4 Consumer Healthcare sales $606.9M
Subscribe for More Information
07:55 EDTPRGOPerrigo sees FY15 adjusted EPS $7.20-$7.50, consensus $7.53
Subscribe for More Information
07:54 EDTPRGOPerrigo reports Q4 adjusted gross margin 44.5%
Subscribe for More Information
07:53 EDTPRGOPerrigo reports Q4 adjusted EPS $1.74 consensus $1.55
Subscribe for More Information
August 13, 2014
15:05 EDTPRGONotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use